Sep 22, 2022 | Press Releases
MARLBOROUGH, Mass., Sept. 22, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
Sep 12, 2022 | Press Releases
MARLBOROUGH, Mass., Sept. 12, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
Aug 11, 2022 | Press Releases
Initiated dosing of subjects and enrollment ongoing in the first-in-human clinical study of PH-762 for the treatment of advanced melanoma; expect to announce top-line data from the first group of subjects in Q1 2023 Expects to initiate a clinical trial evaluating the...
Jun 6, 2022 | Press Releases
MARLBOROUGH, Mass., June 6, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
May 16, 2022 | Press Releases
MARLBOROUGH, Mass., May 16, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
May 12, 2022 | Press Releases
First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-enabling studies for PH-894 in the second half of 2022 MARLBOROUGH, Mass., May 12, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a...